PMID: 2507556Aug 1, 1989Paper

Clinical pharmacokinetics of intravenous flecainide in critically ill patients

Journal of Clinical Pharmacy and Therapeutics
G SangradorP Ibáñez

Abstract

Plasma flecainide (FLC) levels versus time were measured in a group of 10 acute myocardial infarction (AMI) patients at our Intensive Care Unit. These patients were treated with single doses of 150 mg FLC as a 30-min intravenous infusion. Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively. Flecainide pharmacokinetics fitted an open two-compartment model, with a rapid distribution phase and a slow elimination phase. Mean values for the terminal plasma half-life (t1/2 beta) was 22.0 +/- 9.7 h and the volume of distribution (V beta) was 7.99 +/- 3.02 1/kg. FLC is different to other i.v. antiarrhythmics in having a prolonged plasma half-life which is a decided advantage. In contrast to lidocaine, FLC has a pharmacokinetic profile that enables it to be used for treating ventricular arrhythmia without constant-rate i.v. infusion and without the need for complicated loading dosages in order to avoid a 'pharmacokinetic dip' over the first hour of treatment.

References

Sep 1, 1986·British Journal of Clinical Pharmacology·T B Tjandra-MagaP J De Schepper
Dec 1, 1987·Therapeutic Drug Monitoring·R E CoxonG Gallacher
Jan 1, 1988·Intensive Care Medicine·A BorgeatR Chiolero
Apr 1, 1988·Journal of Clinical Pharmacy and Therapeutics·G R Bailie, S Waldek
Apr 1, 1984·Journal of Clinical Pharmacology·E M Vaughan Williams
Feb 27, 1984·The American Journal of Cardiology·G J Conard, R E Ober

❮ Previous
Next ❯

Citations

Apr 1, 2008·Cardiology·Stephen M S TingNeil S Sheerin
Apr 17, 2003·Neonatal Network : NN·Susan Givens Bell
Sep 2, 1999·Anaesthesia and Intensive Care·M A CorkeronL Dusci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

© 2022 Meta ULC. All rights reserved